Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P12644
UPID:
BMP4_HUMAN
Alternative names:
Bone morphogenetic protein 2B
Alternative UPACC:
P12644; Q9UM80
Background:
Bone morphogenetic protein 4 (BMP4), also known as Bone morphogenetic protein 2B, is a pivotal growth factor belonging to the TGF-beta superfamily. It orchestrates numerous developmental processes, including neurogenesis, vascular development, angiogenesis, and osteogenesis. BMP4 triggers the canonical BMP signaling cascade by interacting with BMPR1A and BMPR2 receptors, leading to the phosphorylation of SMAD1/5/8, which modulate gene transcription in the nucleus. Additionally, BMP4 can activate non-canonical pathways such as ERK/MAP kinase, PI3K/Akt, or SRC cascades.
Therapeutic significance:
BMP4's involvement in diseases like Microphthalmia, syndromic 6, and Non-syndromic orofacial cleft 11 underscores its potential as a target for therapeutic intervention. Understanding the role of Bone morphogenetic protein 4 could open doors to potential therapeutic strategies, particularly in addressing congenital anomalies and promoting tissue regeneration.